Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANC-DC/S1: S-1 plus WT1-pulsed dendritic cell vaccine vs S-1 alone after curative resection for pancreatic cancer
jRCTc031190107Phase 2Suspended
- Start
- Apr 2020
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) comparing S-1 plus WT1 peptide-pulsed dendritic cell vaccine with S-1 monotherapy (2 arms). Primary endpoint: Relapse-free survival. Started Apr 2020; status: suspended.
02
Drugs
tegafurWT1 peptide-pulsed dendritic cell vaccine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTc031190107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTc031190107.